These companies need ample free cash flow to fund their R&D activities. Factors Shaping the Future of the Medical-Drugs Industry ... a phase I clinical dose escalation study that demonstrated ...

This initial dose-escalation study demonstrated a favorable safety profile ... candidates are built on the Company's deep expertise in myeloid biology and cancer drug development. The Company's ...

This initial dose-escalation ... No drug-related serious adverse events (SAEs) were reported One NSCLC patient from the 10 mg/kg cohort had an unconfirmed partial response and remains on study ...

This initial dose-escalation study demonstrated a favorable safety ... Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042 ...

CROs Advance Pharmaceutical Innovation with Thermo Fisher Scientific In today’s fast-paced pharmaceutical landscape, Contract ...

This initial dose-escalation study demonstrated a favorable safety ... “BDC-3042 deserves rapid development, especially given its enormous commercial potential. We are launching a process ...

Despite promising adherence and persistence data, tirzepatide dose escalation was slower ... of tirzepatide in real-world settings. Study limitations include a lack of full representation of ...

- Conducted under U.S. FDA-cleared IND - Plans for Phase 2 initiation in Q3 2025 and expansion into Peyronie's disease SEOUL, South Korea, May 7, 2025 /PRNewswire/ -- Connext, a clinical stage ...

The clinical trial is being conducted at multiple centers and is an open-label, dose-escalation study which is designed to evaluate the safety, tolerability and early effectiveness of the new ...

Patients & methods: The MTD was determined from dose-limiting toxicities in the first cycle. Targeted therapies directed against the ErbB receptor family pathway include antibodies, such as ...

Biotech companies developing drugs for hard-to-treat diseases and other ailments are being forced to push back clinical trials and drug testing in the wake of mass layoffs at the Food and Drug ...